Loading

Commentary Open Access
Volume 6 | Issue 4 | DOI: https://doi.org/10.33696/cancerimmunol.6.095

A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer

  • 1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • 2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • 3Department of Translational Molecular Pathology and Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  • 4Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA
  • 5Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA
+ Affiliations - Affiliations

Corresponding Author

Johannes F. Fahrmann, JFFahrmann@mdanderson.org

Received Date: August 12, 2024

Accepted Date: October 03, 2024

Author Information X